Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All three claims match the FDA label’s Indications and the stated approval date is not contradicted by the provided excerpts.
Category Scores
Accurate Statements
Sunosi is indicated for the treatment of excessive daytime sleepiness in adults with narcolepsy.
Section 1 (INDICATIONS AND USAGE): “SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy...”
Sunosi is indicated for the treatment of excessive daytime sleepiness in adults with obstructive sleep apnea (OSA).
Section 1 (INDICATIONS AND USAGE): “SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA)”
Unsupported Statements
Sunosi (solriamfetol) was approved by the U.S. Food and Drug Administration (FDA) on February 22, 2019.
The provided label excerpts do not include an FDA approval date, so support cannot be confirmed from the supplied text.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The indication statements are aligned with Section 1. No safety-critical dosing/contraindication/warning claims were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
FDA approval date is not supported by the provided label excerpts.
Suggested Improvement
Omit or verify the approval date using a source that is included in the provided label text; focus on Section 1 indication language.